Biomimetics Nanoplatform for the Treatment of Retinal Diseases

CEVR has developed an innovative eye drug delivery method called the “Biomimetics NanoPlatform” for the precision treatment of retinal diseases. This platform leverage biorecognition to target and deliver drugs directly to the sites of neuroinflammation in the retina, facilitating more controlled drug release. Additionally, it protects unstable and easily degradable drugs, enhancing therapeutic efficacy while reducing side effects.

• This invention addresses the limitations of retinal disease treatments by utilizing natural immune cell membrane materials to create a biomimetic nanodrug delivery platform.
• This platform leverages precise biorecognition to target and deliver drugs directly to sites of neuroinflammation in the retina, facilitating more controlled drug release.
• It protects unstable and easily degradable drugs, enhancing therapeutic efficacy while minimizing off-target effects.

• The nanoplatform leverages the natural chemotaxis and biological receptors of BV2 microglial cell membranes to specifically identify and target inflamed cells in the retina, thereby improving drug delivery accuracy.
• By encapsulating unstable drugs like baicalein, the platform significantly improves their stability against degradation and prolongs their half-life, leading to superior therapeutic outcomes.
• The precise targeting and controlled release of drugs minimize off-target effects, reducing systemic toxicity and side effects compared to conventional treatments.
• The platform neutralizes pro-inflammatory cytokines (e.g., IL-6, TNF-a) and regulates microglial activity, effectively suppressing neurointlammation and protecting retinal neurons.

• Silver Medal at the 2025 International Exhibition of Inventions in Geneva

• The US Provisional Utility Patent Application no is 63/745,306